SickKids Research Institute
2019–2021: Course Director, Society for Paediatric Dermatology Annual Meeting, Toronto 2021
2019–2022: Chair, Strategic Committee, Society for Pediatric Dermatology
2017–Present: Chair, Pediatric Dermatology Research Alliance (PeDRA)
Dr. Elena Pope is an academic paediatrician with over 15 years of special expertise in paediatric skin disorders, involved in all aspects of clinical, education and research pertaining to the specialty. She has a special interest in rare, orphan diseases that require team collaboration and innovative clinical and research approaches. Dr. Pope created/co-created and has led specialized clinics in rare vascular tumors, epidermolysis bullosa, genodermatoses, morphea and cutaneous lymphoma. She is involved in teaching at all levels and research that stems from her clinical interests.
Education and experience
- 1984–1990: MD, Faculty of Pediatrics, The Institute of Medicine and Pharmacology, Bucharest, Romania
- 1994–1995: M.Sc., Pharmacology, University of Toronto, Toronto, Ontario, Canada
- 1995–1996: MD, Ontario International Medical Graduate Program, University of Toronto, Toronto, Ontario, Canada
- 1999: FRCPC Paediatric Fellowship, Royal College of Physicians and Surgeons of Canada, Ottawa, Ontario, Canada
- 2000–2001: Fellowship in Paediatric Dermatology, The Hospital for Sick Children, Toronto, Ontario, Canada
- 2009–2012: Postgraduate Diploma, Clinical Trials Program, London School of Hygiene and Tropical Medicine, United Kingdom
- 2019: Honorary Member, Canadian Dermatology Association
2020–2021: Co-A. Consensus- based recommendations for management of pediatric mycosis fungoides: The ARMFUL (AppRoach Mycosis Fungoides in children) study. Zvuolunov A, Pope E. PeDRA Consensus Grant. ($15,000 USD)
2020–2022: Co-A. Skin Investigation Network of Canada (SkIN Canada). Chan A, Dutz J, Phillip A, Andrews-Clay K, Drucker A, Fradette M, Germain L, Litvinov I, Piguet V, Zhou Y, Grimshaw J. Hedtrich S, Mydlarski R, Biernaskie J, Cross K, Ghahary A, Hedtrich S, Hinz B, Leask A, Moulin V, Reinhardt D, Roy S, Gniadecki R, Mydlarski R, Alhusayen R, Bissonnette R, Papp K, Pope E, Rosen C, Alavi A, Logsetty S, Kalia S, Lui H, Knoppers B, Zawati, M. CIHR – Network Catalyst Grant ($1, 200,000 CAD)
2019–2022: Site-PI. A phase 2 randomized, multicenter, double-blind, vehicle-controlled, 12-week safety, efficacy and systemic exposure study followed by a 12-week open-label extension of Trifarotene (CD5789) cream in adult and children with lamellar ichthyosis. Pope E. Mayne Pharma LLC. ($64,610 CAD)
2019–2020: PI. Epidermolysis Bullosa Clinical Characterization and Outcomes Database. Pope E, Lara-Corrales I. EB Medical Research Foundation. ($12,767 CAD)
2019–2022: PI. The Efficacy and Safety of AVC-516942 (3% Cannabidiol) Cream in patients with Epidermolysis Bullosa: A Phase II/II trial. Pope E, Lara-Corrales I. Avicanna Canada. ($238,195 CAD)
Our busy Dermatology Department sees over 8,000 visits per year spread across two running clinics.
Information about common skin conditions such as eczema, diaper rash, sunburn, warts, head lice, hair loss, birthmarks and more. Also learn about first aid and everyday care so your child can have healthy hair, skin and nails.